Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-20 pm EDT Pre-market 08:49:50 am
14.79 USD +13.86% Intraday chart for Novavax, Inc. 14.62 -1.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novavax: 1st shipment of R21/MatrixM malaria vaccine CF
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... Our Logo
Focus on Nvidia Our Logo
Shah Capital ends campaign against Novavax board after Sanofi deal RE
Novavax Stockholder Shah Capital Withdraws Campaign Against Reelection of Directors MT
Shah Capital withdraws campaign against Novavax directors after Sanofi deal RE
Shah Capital withdraws campaign against three Novavax directors RE
Shah Capital Management Announces Withdrawal of Nominations CI
Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Global markets live: Apple, Sony, Vodafone, Booking, Walmart... Our Logo
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance MT
Novavax Shares Pop Another 50% Following Sanofi Deal DJ
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank... Our Logo
Wall Street closes up ahead of inflation data RE
News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup DJ
US Equity Markets Close Mixed Friday After Consumer Sentiment Falls MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
News Highlights : Top Company News of the Day - Friday at 3 PM ET DJ
Novavax shares soar on license deal with Sanofi RE
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Wall St mixed but headed for weekly gains ahead of inflation data RE
Top MIdday Gainers MT
Chart Novavax, Inc.
More charts
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14.79 USD
Average target price
19.75 USD
Spread / Average Target
+33.54%
Consensus
  1. Stock Market
  2. Equities
  3. NVAX Stock
  4. News Novavax, Inc.
  5. Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW